2Q’17 financial results reflect the first 4 weeks of TYMLOS sales in the U.S. Managed care contracts in place for coverage of over 130 million lives for TYMLOS™ (68% of all Commercial and 28% of ...
Radius Health, Inc. RDUS posted a loss of $1.31 per share in the third quarter of 2017, wider than the loss of $1.07 per share in the year-ago quarter and the Zacks Consensus Estimate loss of $1.24.
Radius Health, Inc.RDUS announced that the first patient has been enroled in the phase I study on pipeline candidate, RAD140. RAD140 is a nonsteroidal selective androgen receptor modulator (SARM) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results